Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003554 · ClinicalTrials.gov registry record · Phase 2
Rituximab in Treating Patients With Multiple Myeloma
A Phase 2 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003554: Completed Phase 2 study, sponsored by The Cleveland Clinic.
NCT00003554 is a Phase 2 study that has completed, run by The Cleveland Clinic. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003554, a Phase 2 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them. PURPOSE: Phase II trial to study the effectiveness of the monoclonal antibody rituximab in treating patients with multiple myeloma that is newly diagnosed.
Interventions
- DRUG prednisone
- BIOLOGICAL rituximab
- DRUG melphalan
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-11 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
What the finished NCT00003554 record still lists
NCT00003554 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which prednisone is the first listed.
NCT00003554 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003554 about?
NCT00003554 is a clinical study titled "Rituximab in Treating Patients With Multiple Myeloma". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them. PURPOSE: Phase II trial to study the effectiveness of the monoclonal antibody rituximab in treating patients with multiple myeloma that is newly diagnosed.
What is the current status of trial NCT00003554?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-11. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00003554?
The interventions under investigation include: prednisone (DRUG), rituximab (BIOLOGICAL), melphalan (DRUG).
Who is sponsoring clinical trial NCT00003554?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia